ITKの過剰発現は,TCR-Ca2+-Calcineurin-NFAT-IFN-γ経路を通じて,DLBCLに対するT細胞細胞毒性を高める
PubMedで要約を見る
まとめ
この要約は機械生成です。インタールイキン2誘導性T細胞キナーゼ (ITK) は,分散型大B細胞リンパ腫 (DLBCL) で表情が低下し,T細胞の抗腫瘍反応を損なう. ITK機能の回復はT細胞の活性とDLBCLの殺戮を強化し,新しい治療戦略を提供します.
科学分野
- 免疫学
- 腫瘍学
- 分子生物学
背景
- 拡散型大B細胞リンパ腫 (DLBCL) は,治療抵抗性および再発性により予後が悪い一般的なノンホッジキンリンパ腫です.
- 既存のDLBCL治療は限界に直面しており,新しい治療戦略の必要性を強調しています.
- インタールイキン2誘導性T細胞キナーゼ (ITK) はT細胞受容体 (TCR) のシグナル伝達に作用するが,DLBCLにおけるその機能は十分に理解されていない.
研究 の 目的
- DLBCLにおけるITKのメカニズム的役割と臨床的重要性を調査する.
- DLBCLにおける抗腫瘍免疫を強化するための治療標的としてのITKの可能性を調査する.
主な方法
- DLBCLにおけるITK発現レベルと患者の生存率と免疫チェックポイントとの相関性を評価するためのバイオ情報分析.
- マウスTリンパ球 (CTLL-2) のITK過剰発現を伴うin vitro実験で,TCRシグナル伝達と免疫細胞機能への影響を評価した.
- ITK過剰発現するT細胞のDLBCL細胞に対する有効性を評価するための共培養モデル.
主要な成果
- ITKはDLBCLにおいて有意に低発現しており,全生存率の低下とプログラム死亡リガンド1 (PD- L1) の発現の低下と相関しています.
- T細胞におけるITK過剰発現はTCR- Ca2+- Calcineurin- NFAT- IFN- γ経路を活性化し,T細胞の増殖,サイトカインの分泌,DLBCL細胞に対する細胞毒性活性を強化した.
- ITK過剰発現するT細胞とリトキシマブを併用した治療は,DLBCLの増殖を有意に抑制し,アポトーシスを誘発した.
結論
- ITKは,TCRシグナル伝達経路を調節することによって,DLBCLにおける抗腫瘍免疫を強化する上で重要な役割を果たします.
- T細胞のITK機能を回復することは,薬剤耐性を克服し,DLBCLの治療結果を改善するための有望な戦略です.
- この研究は,DLBCL治療のためのT細胞機能を活性化する新しい組み合わせ療法の開発のための理論的基礎を提供します.
関連する概念動画
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

